Bioavailability and Bioequivalence Between Two Active Pharmaceutical Ingredient (API) Sources of Opicapone (OPC)
Status:
Completed
Trial end date:
2018-07-24
Target enrollment:
Participant gender:
Summary
This study evaluates the bioavailability and bioequivalence between two active pharmaceutical
ingredient (API) sources of opicapone (OPC) at two different dosage strengths (50 mg and 25
mg) after single and multiple dose administration under fasting conditions in healthy
volunteers and assess soluble catechol O methyltransferase (S-COMT) activity in 2 API sources
of OPC at two different dosage strengths (50 mg and 25 mg) after single and multiple dose
administration under fasting conditions in healthy volunteers